Morphosys said more patients would be recruited for a study testing the German biotech company’s most advanced drug against a common type of blood cancer, following an encouraging interim data readout.

Denmark-based Genmab A/S and Janssen Biotech will collaborate on a successor to the multiple myeloma drug Darzalex with the development of a next-generation CD38 antibody product for the treatment of multiple myeloma and diffuse large B-cell lymphoma.

Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.

Kite Pharma Inc. highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD.

The U.S. FDA approved Genentech’s Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with certain blood cancers.